d-LIVER
ICT-enabled, cellular artificial liver system incorporating personalized patient management and support
| Coordinatore | UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: JRO Level 6 Leazes Wing, RVI, Queen Victoria Road 6 contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 14˙309˙163 € |
| EC contributo | 10˙959˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2011-7 |
| Funding Scheme | CP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: JRO Level 6 Leazes Wing, RVI, Queen Victoria Road 6 contact info |
UK (Newcastle upon Tyne) | coordinator | 0.00 |
| 2 |
AT4 wireless, S.A.
Organization address
address: CALLE SEVERO OCHOA 2, PARQUE TECNOLOGICO CAMPANILLAS 2 contact info |
ES (MALAGA) | participant | 0.00 |
| 3 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 0.00 |
| 4 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 0.00 |
| 5 |
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT
Organization address
address: RUE JAQUET DROZ 1 contact info |
CH (NEUCHATEL) | participant | 0.00 |
| 6 |
enablingMNT GMBH
Organization address
address: HOLSTEINISCHE STR 23 contact info |
DE (BERLIN) | participant | 0.00 |
| 7 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: HANSASTRASSE 27C contact info |
DE (MUNCHEN) | participant | 0.00 |
| 8 |
HUMANITAS MIRASOLE SPA
Organization address
address: Via Manzoni, 56 contact info |
IT (ROZZANO-MILAN) | participant | 0.00 |
| 9 |
IXSCIENT LIMITED
Organization address
address: POPES GROVE 76 contact info |
UK (TWICKENHAM MIDDLESEX) | participant | 0.00 |
| 10 |
STAR HEALTHCARE MANAGEMENT GMBH
Organization address
address: PIERSTR 8 contact info |
DE (KOELN) | participant | 0.00 |
| 11 |
STEM CELL SYSTEMS GMBH
Organization address
address: FLUGHAFEN TEMPELHOF, HANGAR VI contact info |
DE (BERLIN) | participant | 0.00 |
| 12 |
STIFTELSEN SINTEF
Organization address
address: STRINDVEIEN 4 contact info |
NO (TRONDHEIM) | participant | 0.00 |
| 13 |
UNIVERSITAT ROVIRA I VIRGILI
Organization address
address: CARRER DE ESCORXADOR contact info |
ES (TARRAGONA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
d-LIVER applies scenario-driven development methodologies to address an unmet need for bio-artificial liver support via continuous detoxification as remote transient therapy at the Point-of-Need. The liver is a complex organ with various vital functions in synthesis, detoxification and regulation; its failure is life-threatening and the only curative treatment is transplantation. Whilst awaiting transplantation, or after liver resection, patients need to be supported with detoxification systems which, currently mainly based on filtration, do not support metabolic liver function. This can only be provided by living cells. Thus, development of ICT-enabled bio-artificial liver support systems with associated remote monitoring to assist in the treatment and management of liver patients in care settings extending from the hospital to the home is essential.nd-LIVER targets sensor-based monitoring of patient health status at home, concentrating on continuous monitoring of physiological parameters and discrete measurement of a defined set of biochemical species. d-LIVER also targets remote monitoring and control of the bio-artificial liver and communication with patient sensor networks and hospital information systems. Systems will be capable of remote, secure communication of the status of both the patient and the bio-artificial liver to central clinical services such that they can schedule swift and beneficial treatment and remedial actions. In this way d-LIVER will provide fundamental advances in liver support by reducing hospitalisation costs while enhancing quality of care and, at the same time, reinforcing European leadership in Personal Health systems.nIn a parallel, high-risk, activity the production of human hepatocytes from pancreatic progenitor cells will be investigated. These would be ideal for use in d-LIVER systems since they may provide an unlimited supply of hepatocytes, which would overcome drawbacks associated with both primary hepatocytes and stem cells.